Carerx Corporation · TSX:CRRX
Carerx — Q3 2024 Earnings Presentation
16 slides from Carerx's earnings presentation, Nov 8, 2024
Slide 1: Q3 2024 Earnings Call
Q3 2024 Earnings Call November 8, 2024
Slide 2: Cautionary Statements
Cautionary Statements Forward Looking Statements Certain of the statements contained in this presentation are "forward looking information within the meaning of applicable Canadian securities legislation. Forward looking information includes, but is not limited to, business strategy, plans and other
Slide 3: Puneet Khanna, President & Chief Executive Officer
Puneet Khanna President & Chief Executive Officer 3
Slide 4: Strategic Accomplishments
Strategic Accomplishments • Operational excellence • Debt management • EBITDA growth 4 A leaner, more efficient platform to capitalize on future bed growth
Slide 5: Q3 2024
Q3 2024 • Revenue in Q3 2024 of $92.8 million • Adjusted EBITDA in Q3 2024 of $7.8 million • Announced new state-of-the-art pharmacy in British Columbia • Appointed new Chief Financial Officer 5
Slide 6: Suzanne Brand, Chief Financial Officer
Suzanne Brand Chief Financial Officer 6
Slide 7: Suzanne Brand, CFO
Suzanne Brand, CFO • Previously CFO of Teva Canada • Extensive experience driving growth and efficiency • Long-term business planning and forecasting • Continuous process improvement • Developing high functioning finance teams • Prioritize profitable growth • Passionate about healthcare and the long
Slide 8: Davide Pernarella, VP Business Planning & Analysis
Davide Pernarella Vice President, Business Planning & Analysis 8
Slide 9: Q3 2024 Financial Results | Revenue
Q3 2024 Financial Results | Revenue (millions) 110 • Average beds serviced of 89,099: -5.1% vs Q3 100 $93.8 $92.0 2023 $92.8 90 • Year-over-year revenue decline primarily driven 80 by a net reduction in average number of beds 70 serviced, partially offset by increase in branded 60 pharmaceutical pri
Slide 10: Q3 2024 Financial Results | Adjusted EBITDA
Q3 2024 Financial Results | Adjusted EBITDA (millions) 10 9 $7.5 $7.8 • Year-over-year increase in Adjusted EBITDA 8 $7.3 primarily the result of efficiencies and cost 7 savings initiatives that commenced during 2H 6 2023 as well as improved supply terms from 5 amended procurement agreement with maj
Slide 11: Q3 2024 Financial Results | Net Income
Q3 2024 Financial Results | Net Income (millions) Q3 2023 Q2 2024 Q3 2024 2 1 • Decrease in net loss driven primarily by decreases in finance costs, in addition to the 0 impact of certain cost savings initiatives that commenced during the second half of 2023 -1 -$0.4 -$1.4 -$1.4 -2 -3 -4 -5 11
Slide 12: Balance Sheet
Balance Sheet (millions except ratio) At Sep 30/24 Cash $8.8 M • Quarter-over-quarter increase in cash balance and decline in net debt due to increase in cash flow from operations and repayment of term and Net Debt1 $38.3M operating loan Net Debt to Adjusted EBITDA2 1.2x 1. Debt = borrowings (princi
Slide 13: Puneet Khanna, President & Chief Executive Officer
Puneet Khanna President & Chief Executive Officer 13
Slide 14: New State-of-the-Art Pharmacy
New State-of-the-Art Pharmacy • Opening new high-volume fulfillment centre in North Burnaby, British Columbia in December 2024 • Advanced high-volume medication packaging technology, optimized workflows and streamlined operations • Designed to enhance service delivery for the homes and residents ser
Slide 15: Growth Strategy
Growth Strategy Organic Bed Wins • Leverage scale & capabilities to provide superior pharmacy services offering • Robust sales and RFP pipeline Existing Partners • Large national and regional customers continue to Growth acquire smaller competitors New Home • Home operators expanding through increas
Slide 16: Questions
eo» CareRx Questions y ‘TE A y\ 1 \(c) THE FUTURE OF SENIOR CARE